QR-koda

Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia

<b>Background:</b> Pembrolizumab monotherapy is the standard first-line treatment for metastatic non-small cell lung cancer (NSCLC) patients whose tumors express a PD-L1 tumor proportion score (TPS) of ≥50%. However, real-world data regarding its effectiveness outside of clinical trials, particularl...

Olles dieđut

Furkejuvvon:
Váldodahkkit: Filip Marković, Mihailo Stjepanović, Milan Rančić, Marina Cekić, Milica Kontić
Materiálatiipa: Artigo
Giella:Inglês
Almmustuhtton: MDPI AG 2025-05-01
Ráidu:Biomedicines
Fáttát:
first-line
high PD-L1 expression
immune check-point inhibitors
non-small cell lung cancer
pembrolizumab
predictive factors
Liŋkkat:https://www.mdpi.com/2227-9059/13/5/1175
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid